Business Context and Reporting Period
Company: Carlsmed, Inc. (CARL)
Filing Type: Form 8-K (Current Report)
Date of Report: January 12, 2026
Reporting Period: Year ended December 31, 2025
Context: The filing announces preliminary and unaudited revenue results for the full year 2025. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text references a press release (Exhibit 99.1) containing the specific financial data but does not explicitly state the numerical values within the body of this 8-K document.
- Revenue: Preliminary and unaudited figures for the year ended December 31, 2025, are announced but not listed in this text.
- Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide clear values for these metrics.
Material Changes
The filing text does not provide specific comparative data or percentage changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for year-over-year analysis.
Guidance, Outlook, and Risks
Management Commentary: The report serves as a notification of the preliminary revenue announcement. No specific forward-looking guidance or detailed management commentary is included in the 8-K text itself.
Risks and Contingencies: The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Unusual Items: None identified in the text provided.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the specific preliminary revenue number for 2025.
- Verify the unaudited nature of the reported figures and compare them against the company's prior guidance or analyst estimates.
- Check for subsequent filings (e.g., 10-K) that will provide audited financial statements and detailed breakdowns of expenses, cash flow, and liquidity.
- Confirm the company's status as an emerging growth company and any implications for financial reporting standards.